Moderna is deprioritizing its flu/COVID combination vaccine in younger adults amid a push to cut about $1.5 billion from its ...

HilleVax reports Q1 2025 financials: $159.5 million in assets, reduced losses, and ongoing vaccine development for norovirus. HilleVax, Inc. announced its financial results for the first quarter ...

Topline data is expected in mid-2025, marking a key milestone in the development of a needle-free, shelf-stable pill vaccine to address norovirus, a leading global cause of acute gastroenteritis.

March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates inadults as well as business development related activities and other strategic ...

April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine ...

Trump team’s $500 million bet on old vaccine technology puzzles scientists ... in cruise ship outbreaks fueled by a new strain of norovirus. So far this year, there have been 16 illness ...

COVID - 19: The Company reported $84 million in Spikevax® sales in the first quarter of 2025, which includes $29 million of U.S. sales and $55 million of international sales. As previously reported, ...

Dog data may help track dangerous disease for humans Government watchdog expects Medicaid work requirement analysis by fall Trump team’s $500 million bet on old vaccine technology puzzles ...